CDC Advisory Committee Presentation on Risk of Myocarditis From mRNA Vaccines ‘Flawed’ • Children's Health Defense

On June 23, the Advisory Committee on Immunization Practices at the CDC met to discuss ongoing reports of myocarditis in young people, particularly young men, after the second dose of mRNA vaccines. However, the purpose of weighing those harms and benefits contained misleading statements and data.

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the day. It's free.

On June 23, the Advisory Committee on Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) met to discuss ongoing reports of myocarditis in young people, particularly young men, after the second dose of mRNA vaccines.

In light of these recent reports, the committee was charged with weighing potential harms and benefits associated with second doses of mRNA vaccines.

Despite the importance and gravity of the topic, and the high level at which this discussion was taking place, the presentation given to the committee for the purpose of weighing those harms and benefits was fundamentally flawed.

“Clinical presentation of myocarditis cases following vaccination has been distinct, occurring most often within one week after dose two, with chest pain as the most common presentation,” said Dr. Grace Lee, co-chair of VaST.

— Robert F. Kennedy Jr (@RobertKennedyJr) June 23, 2021

While misleading statements and data can be found throughout the slidedeck, we will focus on two slides which are most relevant to the decision that was facing ACIP on June 23.

The first of these two slides, below, claims to evaluate the “benefits and risks after dose 2,” presenting what appears to be “COVID-19-Associated Hospitalizations Prevented” by dose 2, against “Cases of Myocarditis” which would be expected to be caused by dose 2.

The second of these slides, below, presents “Predicted cases prevented versus myocarditis cases per million second dose vaccinations.”

The presentation contains much flawed analysis and misleading framings of data. But above all, despite the fact that these slides purport to weigh risks versus benefits of “dose 2” of mRNA vaccines, this analysis assumes that single doses of mRNA vaccines have 0% effectiveness at preventing COVID-19 associated hospitalization, despite the fact that original Phase 3 trials found high single-dose effectiveness even at preventing infection, and real-world data has confirmed high effectiveness of single doses at preventing hospitalizations, including against recent variants of SARS-CoV-2.

In particular, the counterfactual used for the analysis given for this presentation was not delaying second doses in certain age groups or even forgoing them altogether, but suspending all vaccinations in this age group, including for children with conditions placing them at elevated risk of severe outcomes and death, for a period of 4 months all of which exhibit rates of deaths and hospitalization comparable to May.

ACIP cannot do its duty if it does not even address the question before it, which was, most immediately: “do the benefits versus harms of second doses of mRNA vaccines favor giving second doses in younger age groups at this time?”

Answering this question requires understanding not the difference between vaccinating kids and not vaccinating them, but between giving second doses and not giving second doses. The titles of these slides notwithstanding, these slides do not present any data pertinent to that question.

It is possible, however, to reconstruct what a more careful balancing of harms and benefits might look like. The first change we will make is simply to incorporate an analysis of the benefit of a single dose of the Pfizer vaccine for the prevention of COVID-19 hospitalization.

This was recently estimated at 83% against the alpha variant, and 92% against the more recent delta variant, by Public Health England. We will conservatively assume a single-dose effectiveness of 83% against hospitalization for this illustration, versus a two-dose effectiveness of 95%. With these assumptions, the first slide shown earlier appears quite different:

Fewer hospitalizations are avoided in this re-analysis, which only attributes to dose 2 those avoided hospitalizations which would not already have been avoided by dose 1.

After this change, the balance of benefits versus harms is much more delicate, with more cases of hospitalization expected from vaccine-induced myocarditis in 12–17 year olds (even lumping boys and girls together) than COVID-19 associated hospitalizations prevented.

We will consider one further change. The case rate shown on the right-hand side of this figure represents the rate at which CDC-confirmed cases of myocarditis have been recorded through voluntary reporting systems. It is natural to expect this to be an underestimate. Indeed, Israel reported rates of myocarditis between 1 in 3000 and 1 in 6000 in 16–24 year olds, with higher rates among 16–19 year olds than 20–24 year olds.

This is roughly 5 times higher than the rate of CDC confirmed myocarditis cases detected through voluntary reporting. If we use Israel rates as a proxy for expected myocarditis rates, we obtain the following comparison (simply by inflating by a factor of 5 the CDC-confirmed rate in each age group up to 29).

In this re-analysis, we compare COVID-19-associated hospitalizations avoided by the 2nd dose, to rates of myocarditis which would be expected at rates seen in Israel.

In this analysis the harms versus benefits of the second dose appear unfavorable for ages under 25. This is true even though:

The harms versus benefits are particularly bad for 12–17 year olds, as is illustrated if we modify the second CDC slide from above under the assumption that a single dose of mRNA vaccine has 83% VE against severe outcomes, and use rates of myocarditis from Israel as the upper estimate on the number of myocarditis rates (the lower estimates remain unchanged here):

When we account for the marginal benefit of the 2nd dose beyond the 1st dose, rather than attributing all the benefits of vaccination to the 2nd dose, the balancing of harms and benefits appears much more unfavorable in teens.

Note that more than 95% of myocarditis cases detected by the CDC resulted in hospitalization — it seems very likely that second doses of mRNA vaccines will cause more hospitalizations than they will prevent in 12–17 year old boys, and whether that is also true for women will depend heavily on the rate at which the CDC is undercounting myocarditis cases.

In the meantime, note that this balance would look even more unfavorable for second doses if it was restricted to healthy children without health factors placing them at elevated risk for severe disease.

In the meantime, the mortality rate of vaccine-associated myocarditis cases remains uncertain. Under questioning during the meeting, Matthew Oster reported that for myocarditis unrelated to COVID-19 or COVID-19 vaccines, mortality rates are estimated in the range of 4%–9% in the literature.

Fortunately, it seems likely that the rate is not so high for vaccine or COVID-19 associated myocarditis. But the rate is likely not zero, and the CDC is already investigating one possible death associated with a second dose of Pfizer vaccine in a 13 year old, over a time period where no deaths would be expected to be avoided from second doses of mRNA vaccines in this age group.

Originally published by Medium.